Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Accumulated Expenses (2016 - 2025)

Karyopharm Therapeutics' Other Accumulated Expenses history spans 14 years, with the latest figure at $4.6 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 181.11% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, up 181.11%, while the annual FY2025 figure was $4.6 million, 181.11% up from the prior year.
  • Other Accumulated Expenses reached $4.6 million in Q4 2025 per KPTI's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $6.4 million in Q4 2022 to a low of $524000.0 in Q2 2021.
  • Average Other Accumulated Expenses over 5 years is $2.1 million, with a median of $1.8 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: soared 844.99% in 2022, then plummeted 74.18% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $678000.0 in 2021, then skyrocketed by 844.99% to $6.4 million in 2022, then tumbled by 74.18% to $1.7 million in 2023, then dropped by 0.79% to $1.6 million in 2024, then soared by 181.11% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Other Accumulated Expenses are $4.6 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025).